Please login to the form below
Wilson Therapeutics
This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Alexion eyes Soliris combo with $930m deal to buy Achillion
Other bolt-on deals to boost its product portfolio and pipeline include the $1.2bn takeover of Syntimmune and $855m purchase of Wilson Therapeutics last year.
Latest news
-
Pfizer goes big on gene therapy with $500m facility spend
That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a ... It also took a 15% stake in Vivet Therapeutics and its lead
-
Alexion targets RNAi with $637m Dicerna deal
The new deal adds to others made by Alexion this year, including the $855m acquisition of rare disease company Wilson Therapeutics in April and privately-held autoimmune disease specialists Syntimmune in
-
Alexion adds to pipeline with $1.2bn Syntimmune buy
In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase
-
Abingworth raises $315m to expand hunt for promising biotechs
The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back
-
Alexion adds to pipeline rebuild with $855m Wilson buy
$855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Latest appointments
-
IGEM Therapeutics appoints Dr Tim Wilson as CEO
Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. ... Wilson has worked for numerous private and public life science companies in the US and Europe at
-
Therachon strengthens management team
He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
